Akt activity in cancers can either be deregulated by constitutive activation or by mutation of PTEN/MMAC1, a phosphatase that directly counteracts Akt through the dephosphorylation of PI-3-, 4-, and 5-P3 (Stambolic et al, 1998). The gene discussed is AKT1; the disease is cancer.